Coiled Therapeutics' Dr Sotirios Stergiopoulos on Roquefort RTO, AO-252 cancer trial update

Coiled Therapeutics (AIM:COIL) co-founder and incoming executive chair Dr Sotirios Stergiopoulos talked with Proactive's Stephen Gunnion about the company’s planned market debut via a reverse takeover by Roquefort Therapeutics PLC (LSE:ROQ) and the progress of its clinical-stage oncology asset AO-252. Stergiopoulos explained that the transaction will see A2A Pharmaceuticals license AO-252 to Roquefort Therapeutics, with the combined entity eventually adopting the Coiled Therapeutics name. The deal also includes an £8.5 million capital raise, with the majority of the funds allocated to advancing the ongoing clinical study of AO-252. The company’s immediate focus is expanding the current Phase 1 trial, with the goal of reaching 30 to 50 patients by mid-Q3 2026, which will help determine the drug’s maximum tolerated dose and further validate its safety profile. Early clinical observations have already shown encouraging signs, including tumour reductions. Stergiopoulos highlighted the importance of the drug’s safety data, particularly when compared with many existing oncology treatments. According to Stergiopoulos, the study has shown “a tremendous safety profile”, with no significant bone marrow or liver toxicity issues reported so far. This strong safety profile could allow longer treatment durations and open the door for combination therapies. Looking ahead, the company sees significant potential for AO-252 in cancers such as prostate and ovarian cancer, as well as other solid tumour indications. Stergiopoulos noted the broader ambition of the therapy, saying: “To be able to potentially replace chemotherapy out there would be amazing.” Upcoming clinical milestones and data expected in 2026 could also support discussions with larger pharmaceutical partners as the program advances. For more interviews and insights from the global resource and biotech sectors, visit the Proactive YouTube channel, give this video a like, subscribe to the channel and enable notifications so you never miss future content. #CoiledTherapeutics #AO252 #CancerResearch #BiotechInvesting #Oncology #ClinicalTrials #ProstateCancerResearch #OvarianCancerResearch #BiotechNews #HealthcareInnovation #PharmaPartnerships #StockMarketNews